Domov › Difuzni veličcelični B-limfom › New York › New York City
Klinične študije za Difuzni veličcelični B-limfom v New York City, NY
21 študij za Difuzni veličcelični B-limfom išče udeležence na lokacijah v New York City in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Vključevanje udeležencevFaza 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Vključevanje udeležencevFaza 2
- Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Vključevanje udeležencevFaza 3
- Icahn School of Medicine at Mount Sinai ( Site 0164), New York
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Vključevanje udeležencevFaza 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0108), New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Vključevanje udeležencevFaza 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Vključevanje udeležencevFaza 1
- Columbia University, New York
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Vključevanje udeležencevFaza 1/2
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Vključevanje udeležencevFaza 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
A Study of ARC-02 in B-cell NHL
Vključevanje udeležencevFaza 1
- NYU Langone, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Vključevanje udeležencevFaza 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
DALY II USA/ MB-CART2019.1 for DLBCL
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center, New York
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Vključevanje udeležencevFaza 1
- Memorial Sloan Kettering Cancer Center, New York
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Vključevanje udeležencevZgodnja faza 1
- Memorial Sloan Kettering Cancer Center, New York
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Vključevanje udeležencevFaza 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Vključevanje udeležencev
- Columbia University, New York
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Vključevanje udeležencevFaza 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
Vključevanje udeležencev
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only), New York
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Vključevanje udeležencevFaza 2
- Memorial Sloan Kettering Cancer Center, New York
Študije za Difuzni veličcelični B-limfom v drugih mestih
- Baldwin Park, CA19 študij
- Chicago, IL18 študij
- Houston, TX17 študij
- Los Angeles, CA17 študij
- Milwaukee, WI16 študij
- Boston, MA16 študij
- Nashville, TN15 študij
- Philadelphia, PA15 študij
- Portland, OR15 študij
- Durham, NC14 študij
- Dallas, TX13 študij
- Washington, DC12 študij
Druge študije v New York City
- Rak dojke136 študij
- Nemalicelični pljučni rak121 študij
- Rak (vse vrste)109 študij
- Rak prostate103 študij
- Metastatski rak93 študij
- Kolorektalni rak78 študij
- Rak jajčnikov69 študij
- Rak pljuč60 študij
- Množni mielom60 študij
- Rak trebušne slinavke60 študij
- Rak endometrija52 študij
- Akutna mieločna levkemija51 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.